If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

Share Price is delayed by 15 minutes
Get Live Data
2.85    0.05 (1.79%)
Bid:
2.70
Ask:
3.00
Spread: 0.30 (11.111%)
Market Cap: £12.46m
RENX Live PriceLast checked at - London Stock Exchange

Intraday Renalytix Plc Share Chart

Holding(s) in Company

26 Apr 2024 17:34

RNS Number : 2943M
Renalytix PLC
26 April 2024
 

Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS

1a. Identity of the issuer or the underlying issuer of existing shares:

Renalytix PLC

1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of shares

X

An acquisition or disposal of financial instruments

An event changing the breakdown of shares outstanding

X

Other (please specify):

3. Details of person subject to the notification obligation

Name

Pentwater Capital Management LP

City and country of registered office (if applicable)

Naples, United States

4. Full name of shareholder(s) (if different from 3.)

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached:

24/04/2024

6. Date on which issuer notified (DD/MM/YYYY):

26/04/2024

7. Total positions of person(s) subject to the notification obligation

% of shares outstanding (total of 8. A)

% of shares outstanding through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of shares outstanding held in issuer

Resulting situation on the date on which threshold was crossed or reached

4.564%

0.680%

5.244%

8,095,187

Position of previous notification (if

applicable)

4.010000%

Less than 3%

4.859%

 

 

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedv

A: Shares

Class/type ofshares

ISIN code (if possible)

Number of shares outstanding

% of shares outstanding

Direct

 

Indirect

 

Direct

 

Indirect

 

ADR: US75973T1016

1,260,000

0.816%

Equity: GB00BYWL4Y04

5,785,196

3.748%

SUBTOTAL 8. A

7,045,196.00

4.564%

 

 

B 1: Financial Instruments as an entitlement to acquire

Type of financial instrument

Expirationdate

Exercise/Conversion Period

Number shares that may be acquired if the instrument is

exercised/converted.

% of shares outstanding

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect

Type of financial instrument

Expirationdate

Exercise/Conversion Period

Physical or cash

settlement

Number of shares

% of shares outstanding

Swap

Cash Settlement

1,049,991

0.680%

 

SUBTOTAL 8.B.2

1,049,991

0.680%

 

 

 

 

 

 

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer

Full chain of controlled undertakings through which the shares and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity(please add additional rows as necessary)

X

Name

% of shares outstanding if it equals or is higher than the notifiable threshold

% of shares outstanding through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Matthew Halbower

Halbower Holdings Inc.

Pentwater Capital Management LP

4.564%

0.680%

5.244%

 

10. Additional information

 

Place of completion

Naples

Date of completion

26/04/2024

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFLFVRSFIRFIS
Date   Source Headline
7th Jul 20264:36 pmRNSHolding(s) in Company
30th Jun 20267:00 amRNSReal world evidence study data published
29th May 20264:24 pmRNSHolding(s) in Company
27th May 202611:20 amRNSHolding(s) in Company
18th May 20263:52 pmRNSHolding(s) in Company
5th May 20263:26 pmRNSHolding(s) in Company
5th May 20269:39 amRNSHolding(s) in Company
1st May 20269:23 amRNSHolding(s) in Company
29th Apr 20264:17 pmRNSHolding(s) in Company
23rd Apr 202611:46 amRNSHolding(s) in Company
23rd Apr 202611:42 amRNSHolding(s) in Company
22nd Apr 20267:00 amRNSKey milestones achieved for kidneyintelX.dkd
16th Apr 20266:04 pmRNSHolding(s) in Company
16th Apr 20269:16 amRNSHolding(s) in Company
9th Apr 20264:29 pmRNSHolding(s) in Company
7th Apr 20265:25 pmRNSHolding(s) in Company
7th Apr 20265:24 pmRNSHolding(s) in Company
30th Mar 20263:41 pmRNSHolding(s) in Company
26th Mar 20267:00 amRNSHalf-year Report
18th Mar 20261:55 pmRNSHolding(s) in Company
17th Mar 202611:22 amRNSHolding(s) in Company
13th Mar 20262:02 pmRNSHolding(s) in Company
13th Mar 20262:02 pmRNSHolding(s) in Company
27th Feb 20267:00 amRNSHolding(s) in Company
13th Feb 20262:30 pmRNSFurther CEO Share Purchase
13th Feb 20267:00 amRNSDirector/PDMR Shareholding
12th Feb 20267:01 amRNSDirector/PDMR Share Purchase
12th Feb 20267:00 amRNSCEO Share Purchase
11th Feb 20267:00 amRNSH1 Trading update
21st Jan 20263:20 pmRNSHolding(s) in Company
15th Jan 20264:51 pmRNSHolding(s) in Company
12th Jan 20267:00 amRNSThree kidneyintelX.dkd Clinical Integrations
9th Jan 20262:43 pmRNSHolding(s) in Company
6th Jan 20264:28 pmRNSHolding(s) in Company
24th Dec 202512:56 pmRNSHolding(s) in Company
24th Dec 202512:56 pmRNSHolding(s) in Company
23rd Dec 20254:13 pmRNSHolding(s) in Company
23rd Dec 20254:13 pmRNSHolding(s) in Company
19th Dec 202512:18 pmRNSHolding(s) in Company
19th Dec 202512:18 pmRNSHolding(s) in Company
17th Dec 20251:42 pmRNSHolding(s) in Company
16th Dec 20251:51 pmRNSHolding(s) in Company
9th Dec 202510:57 amRNSResult of AGM
9th Dec 20257:00 amRNSAGM Statement
27th Nov 20252:39 pmRNSHolding(s) in Company
25th Nov 20253:44 pmRNSHolding(s) in Company
25th Nov 20257:00 amRNSPlan to Implement ADS Ratio Change
12th Nov 20257:00 amRNSPivotal kidneyintelX.dkd data published
5th Nov 20254:02 pmRNSHolding(s) in Company
4th Nov 20256:05 pmRNSPublication of Annual Report & Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.